Transplant Diagnostics Market: Growth, Development, Trends, Demand, Analysis and Forecast 2026
Transplant
diagnostics involves assessing compatibility between organ donor and
receiver so as to predict any future organ rejection episodes and
have contingencies in place. Number of tests are performed such as
ABO blood group compatibility, tissue typing, cross matching, panel
reactive antibody test, serology screening, and testing for
infectious diseases. Increased understanding of the organ rejection
phenomenon has led to identification of robust biomarkers along with
development of robust biomarker identification tests. Technological
advancements in the molecular and non-molecular assays such as PCR,
and NGS has increased the data throughput.
Some major
players operating in the transplant diagnostics market are Thermo
Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., F.
Hoffman-La Roche Ltd., Immucor, Inc., Becton Dickinson and Company,
bioMérieux S.A., Illumina, Inc., CareDx, Inc., and GenDx.
Download the
PDF brochure :
https://www.coherentmarketinsights.com/insight/request-pdf/1335
Market
Dynamics
Rising prevalence of
chronic diseases leading to multiple organ failures; benefits offered
by transplant diagnostics, which can predict organ rejection episodes
and help in preparing a contingency plan; increasing government
initiatives for organ donation awareness; and research and
development by leading players to enhance transplant diagnostic
products is expected to boost growth of the transplant diagnostics
market over the forecast period. For instance, Natera, Inc. and
University of California, San Francisco (UCSF), announced a research
collaboration in 2016, to study DNA markers of Kidney Transplant
Rejection. Furthermore, in 2016, the U.S. government announced plans
to invest US$ 200 million to shorten the waiting list of organ
transplant patients. These factors are expected to aid in growth of
the market over the forecast period.
Advent of new
diagnostic tests have improved medical outcomes associated with organ
transplants. Organ rejection rate can be minimized by matching the
donor and recipient compatibility before transplantation.
Conventional techniques in transplant diagnostics include analysis of
human leukocyte antigen (HLA). HLA analysis is done in
high-throughput laboratories with a limited staff, which is time
consuming. However, presence of molecular assay technologies, such as
sequencing techniques and PCR-based assays have proved to be
efficient. Genetic information can be interpreted on a large scale by
using advanced next generation sequencing (NGS) technologies at an
affordable price. For instance, Illumina’s MiSeq system offers
high-resolution HLA typing and uses next generation sequencing
technology, which can be used by any laboratory.
Increasing number of
transplantation is expected to increase demand for transplant
diagnostics, in order to reduce episodes of organ rejection. Various
organizations such as World Health Organization (WHO) and World
Health Assembly have implanted action plans such as WHA57.18 to
increase awareness regarding transplantation. National Health Service
(NHS) Blood & Transplant funded a living transplant initiative in
2016, which was led by the National BAME Transplant Alliance, to
increase the number of living transplants from black, Asian, and
minority ethnic (BAME) communities.
Click To
Read More On Transplant
Diagnostics Market
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment